Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas and virtually.
The presentation details are as follows:
- Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
- Abstract Number: 765
- Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
- Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
- Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
Positive
- Abstract accepted for poster presentation at a major oncology conference (SITC)
- Opportunity to showcase research on DNase I targeting and immune checkpoint blockade
Negative
- None.
Details
News Market Reaction – XBIO
The recorded move for XBIO in the trading session of this news was -3.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually.
Details of the presentation are as follows:
Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
Abstract Number: 765
Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
For more information about the conference, visit www.sitcancer.org/2024.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on accesswire.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.